Unlocking the Power of CAR T Immunotherapy: Cellectis Shares Exciting Pre-Clinical Results for Fighting Tough Tumors
Playful and Quirky Look at Cellectis’ Latest Breakthrough NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published an article in Frontiers Bioengineering, demonstrating the efficacy of its TALEN® engineered…